View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

       

News

Regeneus Ltd (ASX:RGS) to Receive Milestone Payment for Successful Phase I

🕔6/21/2017 9:10:44 AM 1446

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it will receive a milestone payment of US$1m from AGC for meeting the primary endpoints of its Phase 1 safety trial of Progenza in patients with knee osteoarthritis. The company reported on the positive results of the trial on 22 May 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) Presentation to ChinaBio Partnering Forum

🕔5/31/2017 8:26:23 AM 1575

Regeneus Ltd (ASX:RGS) is pleased to provide the Company's latest presentation to ChinaBio Partnering Forum.

Read Full Article

Regeneus Ltd (ASX:RGS) Japanese Patent Office to Grant Key Patent for Progenza

🕔5/24/2017 9:20:35 AM 2695

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the Japanese Patent Office has issued a decision to grant a key patent covering the composition, manufacture and use of Progenza stem cell technology.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive Clinical Trial Results for Progenza

🕔5/22/2017 9:52:04 AM 2787

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis, meeting the primary endpoint of safety and tolerability.

Read Full Article

FINANCE VIDEO: Regeneus Ltd (ASX:RGS) CEO John Martin Talks about the Licensing of Progenza in Japan

🕔3/9/2017 9:00:20 AM 8529

With the recent announcement of a significant licensing deal with AGC Ltd in Japan, the company is set to build on their platform for the delivery of Progenza to deal with many healthcare issues from arthritis and pain, to genetic disorders.

Read Full Article

Regeneus Ltd (ASX:RGS) Enters Into Collaborative Agreement With Asahi Glass (TYO:5201) To Commercialize Progenza

🕔1/13/2017 2:19:42 PM 7206

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, announced that it has entered into a strategic collaboration and licensing agreement with AGC Asahi Glass (AGC) (TYO:5201), a world-leading manufacturer of glass, chemicals, high-tech materials and biopharmaceuticals.

Read Full Article

Regeneus Ltd (ASX:RGS) FY16 Results Presentation

🕔8/24/2016 9:59:03 AM 2624

Regeneus Ltd (ASX:RGS) are pleased to provide a Company Presentation for the Full Year Results for FY16.

Read Full Article

Regeneus Ltd (ASX:RGS) FY16 Results Announcement

🕔8/24/2016 9:48:39 AM 2655

Regeneus Ltd (ASX:RGS today reported its 2016 financial results and business update. During the year, the company made significant progress on the development of its portfolio of cell-based therapies for the treatment of osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases for the human and animal health markets.

Read Full Article

Regeneus Ltd (ASX:RGS) Appendix 4E and Annual Report 2016

🕔8/24/2016 9:34:59 AM 2577

Regeneus Ltd (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases.

Read Full Article

Regeneus Ltd (ASX:RGS) European Patent to Grant on Stem Cell Secretions Technology for Acne

🕔8/1/2016 10:33:03 AM 4533

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the European Patent Office has decided to grant a patent covering the use of the company's stem cell secretions technology for the topical treatment of acne.

Read Full Article
###

57,853 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 231) (Last 30 Days: 1883) (Since Published: 30943) 

Markets ASX:RGS

Company Data

    Headquarters
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports

Presentations

Research Report

Quarterly Report

Social Media